Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21403730 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2NFKB1NFKB2RELAHDAC6 | |
| SCHEMBL21403608 | 0.83 | L3MBTL1 (0.32) | HDAC6MEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL6935567 | 0.83 | L3MBTL1 (0.32) | HDAC6MEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL10634002 | 0.83 | L3MBTL1 (0.32) | HDAC6MEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL27309422 | 0.83 | NFKB1 (0.38) | SMN1; SMN2NFKB1NFKB2RELAHDAC6 | |
| SCHEMBL21403646 | 0.82 | HDAC6 (0.31) | HDAC6MEN1KMT2A | |
| SCHEMBL25838348 | 0.81 | MEN1 (0.36) | HDAC6MEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL18649433 | 0.81 | SMN1; SMN2 (0.35) | SMN1; SMN2NFKB1NFKB2RELAHDAC6 | |
| SCHEMBL25165313 | 0.78 | HDAC6 (0.33) | HDAC6MEN1KMT2AHDAC1HDAC2 | |
| SCHEMBL21403595 | 0.77 | FAAH (0.31) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774843-B1 | DIPEPTIDE PIPERIDINE DERIVATIVES | MOLECURE SA (PL) | 2022-05-25 | — | — | EP | disclosed |
| US-10851099-B2 | Dipeptide piperidine derivatives | Oncoarendi Therapeutics S.A. (PL) | 2020-12-01 | — | — | US | disclosed |
| US-20190300525-A1 | DIPEPTIDE PIPERIDINE DERIVATIVES | Oncoarendi Therapeutics S.A. (PL) | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851099-B2 | Dipeptide piperidine derivatives | ARG1, ARG2, PEPD | SMN1; SMN2 1563/4885NFKB1 324/4885NFKB2 440/4885 |
| US-20190300525-A1 | DIPEPTIDE PIPERIDINE DERIVATIVES | ARG1, ARG2, PEPD | SMN1; SMN2 1563/4885NFKB1 324/4885NFKB2 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.